Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK5 | O95279 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | KCNK17 | Q96T54 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16374958 | 0.88 | KCNK3 (0.44) | METKCNK3KCNK5KCNA5KCNK17 | |
| SCHEMBL16374956 | 0.86 | PPARD (0.46) | METKCNK3KCNK5KCNA5KCNK17 | |
| SCHEMBL92995 | 0.86 | CNR2 (0.52) | CNR2FAAH | |
| SCHEMBL15978569 | 0.86 | MET (0.43) | METKCNK3KCNK5KCNA5KCNK17 | |
| SCHEMBL18532059 | 0.84 | KCNA5 (0.52) | METKCNK3KCNK5KCNA5KCNK17 | |
| SCHEMBL16453348 | 0.81 | MET (0.39) | METKCNK3KCNK5KCNA5KCNK17 | |
| SCHEMBL16375008 | 0.77 | MET (0.44) | METKCNK3KCNK5KCNA5KCNK17 | |
| SCHEMBL15015194 | 0.76 | PDE10A (0.43) | METKCNK3KCNK5KCNA5KCNK17 | |
| SCHEMBL8981503 | 0.76 | CNR2 (0.54) | CNR2FAAH | |
| SCHEMBL13039505 | 0.74 | CCNE2 (0.40) | CNR2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334858-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2017-11-23 | — | — | US | disclosed |
| US-9573965-B2 | Process for the preparation of Dolutegravir | AUROBINDO PHARMA LTD (IN) | 2017-02-21 | — | — | US | disclosed |
| US-20160333026-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2016-11-17 | — | — | US | disclosed |
| EP-3045461-A1 | Processes for preparing dolutegravir and analogues thereof | LEK Pharmaceuticals d.d. (SI) | 2016-07-20 | — | — | EP | disclosed |
| US-20160108058-A1 | An improved process for the preparation of Dolutegravir | AUROBINDO PHARMA LTD. (IN) | 2016-04-21 | — | — | US | disclosed |
| WO-2015110897-A2 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2015-07-30 | — | — | WO | disclosed |
| WO-2015019310-A1 | PROCESS FOR THE PREPARATION OF DOLUTE-GRAVIR AND INTERMEDIATES THEREOF | MYLAN LABORATORIES LTD (IN) | 2015-02-12 | — | — | WO | disclosed |
| WO-2015001572-A2 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334858-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | CYP3A4, DHPS, MVD | MET 2886/4885KCNK3 2177/4885KCNK5 1165/4885 |
| US-20160108058-A1 | An improved process for the preparation of Dolutegravir | XDH, TBK1, POLR2H | MET 4128/4885KCNK3 2878/4885KCNK5 1573/4885 |
| US-20160333026-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CYP3A5, SAMHD1, CYP3A43 | MET 3696/4885KCNK3 1223/4885KCNK5 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.